ALGAE Fundamental Analysis - FERMENTALG

Fundamental Rating

ALGAE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 75 industry peers in the Chemicals industry. ALGAE may be in some trouble as it scores bad on both profitability and health. ALGAE shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALGAE has reported negative net income.

ALGAE had a negative operating cash flow in the past year.

ALGAE had negative earnings in each of the past 5 years.

In the past 5 years ALGAE always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -24.55%, ALGAE is not doing good in the industry: 92.00% of the companies in the same industry are doing better.

The Return On Equity of ALGAE (-38.47%) is worse than 86.67% of its industry peers.

		Industry Rank	Sector Rank
ROA	-24.55%
ROE	-38.47%
ROIC	N/A

ROA(3y)-23.55%

ROA(5y)-19.66%

ROE(3y)-36.03%

ROE(5y)-31.3%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 20.94%, ALGAE is not doing good in the industry: 69.33% of the companies in the same industry are doing better.

In the last couple of years the Gross Margin of ALGAE has declined.

ALGAE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	20.94%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-14.82%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALGAE does not have a ROIC to compare to the WACC, probably because it is not profitable.

ALGAE has more shares outstanding than it did 1 year ago.

The number of shares outstanding for ALGAE has been increased compared to 5 years ago.

ALGAE has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of 1.27, we must say that ALGAE is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of ALGAE (1.27) is worse than 81.33% of its industry peers.

ALGAE has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.

Looking at the Debt to Equity ratio, with a value of 0.12, ALGAE is in the better half of the industry, outperforming 78.67% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.12
Debt/FCF	N/A
Altman-Z	1.27

ROIC/WACCN/A

WACC5.96%

2.3 Liquidity

ALGAE has a Current Ratio of 1.92. This is a normal value and indicates that ALGAE is financially healthy and should not expect problems in meeting its short term obligations.

ALGAE has a Current ratio (1.92) which is in line with its industry peers.

ALGAE has a Quick Ratio of 1.86. This is a normal value and indicates that ALGAE is financially healthy and should not expect problems in meeting its short term obligations.

ALGAE's Quick ratio of 1.86 is amongst the best of the industry. ALGAE outperforms 84.00% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.92
Quick Ratio	1.87

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 57.69% over the past year.

Looking at the last year, ALGAE shows a very strong growth in Revenue. The Revenue has grown by 59.05%.

Measured over the past years, ALGAE shows a very strong growth in Revenue. The Revenue has been growing by 43.52% on average per year.

EPS 1Y (TTM)57.69%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%60%

Revenue 1Y (TTM)59.05%

Revenue growth 3Y26.74%

Revenue growth 5Y43.52%

Sales Q2Q%20.35%

3.2 Future

The Earnings Per Share is expected to grow by 17.96% on average over the next years. This is quite good.

ALGAE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 39.99% yearly.

EPS Next Y30.77%

EPS Next 2Y30.09%

EPS Next 3Y27.59%

EPS Next 5Y17.96%

Revenue Next Year13.04%

Revenue Next 2Y50.36%

Revenue Next 3Y56.76%

Revenue Next 5Y39.99%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALGAE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALGAE. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ALGAE's earnings are expected to grow with 27.59% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y30.09%

EPS Next 3Y27.59%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALGAE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

FERMENTALG

EPA:ALGAE (12/24/2025, 7:00:00 PM)

0.427

+0.01 (+1.91%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)10-07 2025-10-07

Earnings (Next)01-12 2026-01-12

Inst Owners25.5%

Inst Owner ChangeN/A

Ins Owners2.02%

Ins Owner ChangeN/A

Market Cap38.36M

Revenue(TTM)12.78M

Net Income(TTM)-11.54M

Analysts84.44

Price Target0.73 (70.96%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)-28.57%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	3
P/FCF	N/A
P/OCF	N/A
P/B	1.28
P/tB	2.56
EV/EBITDA	N/A

EPS(TTM)-0.12

EYN/A

EPS(NY)-0.04

Fwd EYN/A

FCF(TTM)-0.06

FCFYN/A

OCF(TTM)-0.05

OCFYN/A

SpS0.14

BVpS0.33

TBVpS0.17

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-24.55%
ROE	-38.47%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	20.94%
FCFM	N/A

ROA(3y)-23.55%

ROA(5y)-19.66%

ROE(3y)-36.03%

ROE(5y)-31.3%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-14.82%

GM growth 5YN/A

F-Score5

Asset Turnover0.27

Health

		Industry Rank	Sector Rank
Debt/Equity	0.12
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	18.55%
Cap/Sales	3.99%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.92
Quick Ratio	1.87
Altman-Z	1.27

F-Score5

WACC5.96%

ROIC/WACCN/A

Cap/Depr(3y)32.25%

Cap/Depr(5y)108.19%

Cap/Sales(3y)12.01%

Cap/Sales(5y)34.65%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)57.69%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%60%

EPS Next Y30.77%

EPS Next 2Y30.09%

EPS Next 3Y27.59%

EPS Next 5Y17.96%

Revenue 1Y (TTM)59.05%

Revenue growth 3Y26.74%

Revenue growth 5Y43.52%

Sales Q2Q%20.35%

Revenue Next Year13.04%

Revenue Next 2Y50.36%

Revenue Next 3Y56.76%

Revenue Next 5Y39.99%

EBIT growth 1Y15.76%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year41.18%

EBIT Next 3Y33.56%

EBIT Next 5Y22.54%

FCF growth 1Y49.26%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y50.34%

OCF growth 3YN/A

OCF growth 5YN/A

FERMENTALG / ALGAE.PA FAQ

What is the ChartMill fundamental rating of FERMENTALG (ALGAE.PA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ALGAE.PA.

What is the valuation status of FERMENTALG (ALGAE.PA) stock?

ChartMill assigns a valuation rating of 1 / 10 to FERMENTALG (ALGAE.PA). This can be considered as Overvalued.

Can you provide the profitability details for FERMENTALG?

FERMENTALG (ALGAE.PA) has a profitability rating of 0 / 10.

What is the financial health of FERMENTALG (ALGAE.PA) stock?

The financial health rating of FERMENTALG (ALGAE.PA) is 3 / 10.

FERMENTALG (ALGAE.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

FERMENTALG / ALGAE.PA FAQ

What is the ChartMill fundamental rating of FERMENTALG (ALGAE.PA) stock?

What is the valuation status of FERMENTALG (ALGAE.PA) stock?

Can you provide the profitability details for FERMENTALG?

What is the financial health of FERMENTALG (ALGAE.PA) stock?